MedPage Today June 5, 2024
Joyce Frieden

— “Even with some variation, there’s still reasonably good protection”

An FDA advisory committee voted unanimously, 16-0, Wednesday to recommend that the COVID-19 vaccines for the 2024-2025 season target the JN.1 strain of the virus.

“From my review of the data, it appeared that the newer variants that are appearing — KP.2, KP.3, and maybe some others that are coming up — the potential for immunogenicity from a JN.1 vaccine to cover those variants seems to be pretty good,” said Archana Chatterjee, MD, PhD, of Rosalind Franklin University of Medicine and Science in Chicago. “Antigenically they are close, and from the experience we had with [the] XBB [strain], it appears even with some variation, there’s still reasonably good protection. So...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Healthcare System, Pharma / Biotech, Public Health / COVID
Related Articles:
FDA warns GLP-1 compounder over safety rules
GLP-1 drug approvals: A breakdown
Rethinking FDA’s Accelerated Approval Pathway: New Draft Guidances and Implications for Drug Companies
FDA approves Novo Nordisk's Ozempic to treat chronic kidney disease in those with diabetes, expanding its use
Certainty vs. speed: How do patients feel about the tradeoff for new cancer drugs?

Share This Article